Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor.

作者: Wang Kai , Shan Yating , Ma Lin , Yang Kaiyong , Hua Baojin

DOI: 10.1016/J.BCP.2018.03.022

关键词: Cancer cellMultiple drug resistanceDrugCancer researchP110αChemistryImmunofluorescenceBreast cancerDownregulation and upregulationPI3K/AKT/mTOR pathway

摘要: … In this study, we found for the first time that toosendanin (TSN), a triterpenoid extracted from the traditional Chinese medicine Melia toosendan Sieb et Zucc, could successfully reverse …

参考文章(50)
Maria Vittoria Dieci, Valentina Guarneri, PIK3CA: a Target or a Marker in Breast Cancers Current Breast Cancer Reports. ,vol. 7, pp. 161- 169 ,(2015) , 10.1007/S12609-015-0184-1
Rebecca Simstein, Matthew Burow, Amanda Parker, Christopher Weldon, Barbara Beckman, Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System: Experimental Biology and Medicine. ,vol. 228, pp. 995- 1003 ,(2003) , 10.1177/153537020322800903
Suresh V Ambudkar, Chava Kimchi-Sarfaty, Zuben E Sauna, Michael M Gottesman, P-glycoprotein: from genomics to mechanism Oncogene. ,vol. 22, pp. 7468- 7485 ,(2003) , 10.1038/SJ.ONC.1206948
Brendan D. Manning, Lewis C. Cantley, AKT/PKB signaling: navigating downstream. Cell. ,vol. 129, pp. 1261- 1274 ,(2007) , 10.1016/J.CELL.2007.06.009
Hassan, Chemotherapy for breast cancer (Review) Oncology Reports. ,vol. 24, pp. 1121- 1131 ,(2010) , 10.3892/OR_00000963
Justin Cidado, Ben Ho Park, Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy Journal of Mammary Gland Biology and Neoplasia. ,vol. 17, pp. 205- 216 ,(2012) , 10.1007/S10911-012-9264-2
Daniëlle A. E. Raats, Menno T. de Bruijn, Ernst J. A. Steller, Benjamin L. Emmink, Inne H. M. Borel-Rinkes, Onno Kranenburg, Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. Cellular Oncology. ,vol. 34, pp. 307- 313 ,(2011) , 10.1007/S13402-011-0026-8